Ultragenyx Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US90400D1081

SecurityRARE / Ultragenyx Pharmaceutical Inc.
InstitutionTruist Financial Corp
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Truist Financial Corp closes position in RARE / Ultragenyx Pharmaceutical Inc.

On November 3, 2025 - Truist Financial Corp filed a 13F-HR form disclosing ownership of 0 shares of Ultragenyx Pharmaceutical Inc. (US:RARE) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on July 18, 2025 disclosing 5,503 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-03 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -5,503 -100.00 0 -100.00
2025-07-18 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,503 -4,080 -42.58 200 -42.36 0.0003
2025-04-29 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 9,583 -1,103 -10.32 347 -22.72 0.0006
2025-01-31 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 10,686 -1,615 -13.13 450 -34.26 0.0007
2024-11-13 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 12,301 2,510 25.64 683 69.90 0.0011
2024-08-21 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 9,791 -319 -3.16 402 -14.83 0.0006
2024-05-13 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 10,110 -1,613 -13.76 472 -15.71 0.0007
2024-02-02 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,723 -7,291 -38.35 561 -17.28 0.0009
2023-11-14 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 19,014 -599 -3.05 678 -25.11 0.0011
2023-08-01 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 19,613 4,726 31.75 905 51.68 0.0015
2023-05-05 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 14,887 655 4.60 597 -9.56 0.0010
2023-02-17 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 14,232 2,710 23.52 659 38.16 0.0012
2022-10-26 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,522 3,883 50.83 477 4.61 0.0009
2022-07-22 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 7,639 -65 -0.84 456 -18.43 0.0008
2022-04-22 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 7,704 1,318 20.64 559 4.10 0.0009
2022-02-14 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,386 7 0.11 537 -6.61 0.0008
2021-11-05 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,379 195 3.15 575 -2.54 0.0009
2021-08-16 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,184 -323 -4.96 590 -20.38 0.0010
2021-05-17 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,507 391 6.39 741 -12.41 0.0013
2021-11-19 2020-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,116 863 16.43 846 95.83 0.0016
2021-02-18 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 10,618 5,365 1,469 0.0027
2021-11-05 2020-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,253 654 14.22 432 20.00 0.0009
2020-11-13 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,253 654 432 0.0009
2021-11-16 2020-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 4,599 4,599 360 0.0008
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 4,599 360 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.